

# Miricor

Miricor Enterprises Holdings Limited

卓珈控股集團有限公司

## INTERIM REPORT 2021/22



Incorporated in the Cayman Islands with limited liability

於開曼群島註冊成立的有限公司

Stock Code 股份代號：1827

## CONTENTS

2	Corporate Information
4	Highlights
5	Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
6	Condensed Consolidated Statement of Financial Position
8	Condensed Consolidated Statement of Changes in Equity
9	Condensed Consolidated Statement of Cash Flows
11	Notes to the Condensed Consolidated Financial Statements
26	Management Discussion and Analysis
30	Other Information

## 目錄

公司資料
摘要
簡明綜合損益及其他全面收益表
簡明綜合財務狀況表
簡明綜合權益變動表
簡明綜合現金流量表
簡明綜合財務報表附註
管理層討論及分析
其他資料

## CORPORATE INFORMATION

### 公司資料

#### Board of directors

##### **Executive Directors**

Ms. LAI Ka Yee Gigi (*Chairlady and Chief Executive Officer*)

Mr. HO Tsz Leung Lincoln

Dr. LAM Ping Yan

##### **Independent Non-Executive Directors**

Mr. CHENG Fu Kwok David

Mr. CHENG Yuk Wo

Mr. LI Wai Kwan

#### Audit committee

Mr. CHENG Yuk Wo (*Chairman*)

Mr. CHENG Fu Kwok David

Mr. LI Wai Kwan

#### Remuneration committee

Mr. CHENG Yuk Wo (*Chairman*)

Ms. LAI Ka Yee Gigi

Mr. LI Wai Kwan

#### Nomination committee

Ms. LAI Ka Yee Gigi (*Chairlady*)

Mr. CHENG Fu Kwok David

Mr. CHENG Yuk Wo

#### Authorised representatives

Mr. HO Tsz Leung Lincoln

Mr. LO Tai On

#### Company secretary

Mr. LO Tai On

#### Auditor

Ernst & Young

*Certified Public Accountants*

*Registered Public Interest Entity Auditor*

27/F, One Taikoo Place

979 King's Road

Quarry Bay

Hong Kong

#### 董事會

##### **執行董事**

黎珈而女士 (*主席兼行政總裁*)

何子亮先生

林秉恩醫生

##### **獨立非執行董事**

鄭輔國先生

鄭毓和先生

李偉君先生

#### 審核委員會

鄭毓和先生 (*主席*)

鄭輔國先生

李偉君先生

#### 薪酬委員會

鄭毓和先生 (*主席*)

黎珈而女士

李偉君先生

#### 提名委員會

黎珈而女士 (*主席*)

鄭輔國先生

鄭毓和先生

#### 授權代表

何子亮先生

羅泰安先生

#### 公司秘書

羅泰安先生

#### 核數師

安永會計師事務所

*執業會計師*

*註冊公眾利益實體核數師*

香港

鰂魚涌

英皇道979號

太古坊一座27樓

## Registered office in Cayman Islands

Cricket Square, Hutchins Drive  
P.O. Box 2681  
Grand Cayman, KY1-1111  
Cayman Islands

## 開曼群島註冊辦事處

Cricket Square, Hutchins Drive  
P.O. Box 2681  
Grand Cayman, KY1-1111  
Cayman Islands

## Headquarters and principal place of business in Hong Kong

18/F, Nan Fung Tower  
88 Connaught Road Central  
Central  
Hong Kong

## 香港總部及主要營業地點

香港  
中環  
干諾道中88號  
南豐大廈18樓

## Cayman Islands principal share registrar and transfer office

Conyers Trust Company (Cayman) Limited  
Cricket Square, Hutchins Drive  
P.O. Box 2681  
Grand Cayman, KY1-1111  
Cayman Islands

## 開曼群島主要股份過戶登記處

Conyers Trust Company (Cayman) Limited  
Cricket Square, Hutchins Drive  
P.O. Box 2681  
Grand Cayman, KY1-1111  
Cayman Islands

## Hong Kong share registrar

Tricor Investor Services Limited  
Level 54, Hopewell Centre  
183 Queen's Road East  
Hong Kong

## 香港股份過戶登記處

卓佳證券登記有限公司  
香港  
皇后大道東183號  
合和中心54樓

## Principal banker

The Bank of East Asia, Limited  
Shop A-C, G/F  
Easey Commercial Building  
253-261 Hennessy Road  
Wanchai  
Hong Kong

## 主要往來銀行

東亞銀行有限公司  
香港  
灣仔  
軒尼詩道253-261號  
依時商業大廈  
地下A-C號

## Public relations consultant

Strategic Financial Relations Limited  
2401-2, Admiralty Centre 1,  
18 Harcourt Road, Hong Kong

## 公關顧問

縱橫財經公關顧問有限公司  
香港夏慤道18號  
海富中心第一期2401-2室

## Stock code

1827

## 股份代號

1827

## Company website

[www.miricor.com](http://www.miricor.com)

## 公司網址

[www.miricor.com](http://www.miricor.com)

## HIGHLIGHTS

### 摘要

- |   |  |
|---|--|
| <ul style="list-style-type: none"><li>• The Group's revenue amounted to approximately HK\$199.7 million for the six months ended 30 September 2021, representing an increase of approximately HK\$145.2 million or 266.4% as compared to approximately HK\$54.5 million for the six months ended 30 September 2020.</li><li>• Profit attributable to the owners of the Company was approximately HK\$53.9 million for the six months ended 30 September 2021 (six months ended 30 September 2020: loss of approximately HK\$6.2 million).</li><li>• The Board does not recommend the payment of an interim dividend for the six months ended 30 September 2021 (six months ended 30 September 2020: Nil).</li></ul> | <ul style="list-style-type: none"><li>• 截至2021年9月30日止六個月，本集團的收益約為199.7百萬港元，與截至2020年9月30日止六個月約54.5百萬港元相比增加約145.2百萬港元或266.4%。</li><li>• 截至2021年9月30日止六個月，本公司擁有人應佔溢利約為53.9百萬港元(截至2020年9月30日止六個月：虧損約6.2百萬港元)。</li><li>• 董事會不建議就截至2021年9月30日止六個月派付中期股息(截至2020年9月30日止六個月：無)。</li></ul> |
|---|--|

# CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

## 簡明綜合損益及其他全面收益表

For the six months ended 30 September 2021

截至2021年9月30日止六個月

		Six months ended 30 September 截至9月30日止六個月		
		2021 HK\$'000 千港元 (Unaudited) (未經審核)	2020 HK\$'000 千港元 (Unaudited) (未經審核)	
	Notes 附註			
<b>REVENUE</b>	收益	4	199,730	54,500
Other income	其他收入	4	424	7,406
Cost of inventories and consumables	存貨及消耗品成本		(13,317)	(5,593)
Staff costs	員工成本		(56,351)	(32,726)
Property rentals and related expenses	物業租金及相關開支		(17,527)	(10,447)
Depreciation of property, plant and equipment	物業、廠房及設備折舊		(7,342)	(6,398)
Other expenses	其他開支		(43,873)	(13,409)
Finance costs	財務成本	6	(1,177)	(980)
<b>PROFIT/(LOSS) BEFORE TAX</b>	除稅前溢利/(虧損)	5	60,567	(7,647)
Income tax (expense)/credit	所得稅(開支)/抵免	7	(6,648)	1,458
<b>PROFIT/(LOSS) FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE COMPANY</b>	本公司擁有人應佔期內 溢利/(虧損)		53,919	(6,189)
<b>OTHER COMPREHENSIVE INCOME</b>	其他全面收入			
<i>Item that may be reclassified subsequently to profit or loss:</i>	<i>其後可能重新分類至損益的 項目：</i>			
Exchange differences on translation of foreign operations	換算海外業務的匯兌差額		126	30
<b>TOTAL COMPREHENSIVE INCOME/ (LOSS) FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE COMPANY</b>	本公司擁有人應佔期內 全面收入/(虧損)總額		54,045	(6,159)
<b>EARNINGS/(LOSS) PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY</b>	本公司普通股權益持有人 應佔每股盈利/(虧損)			
— Basic and diluted	— 基本及攤薄	9	HK13.48 cents 港仙	HK(1.55) cents 港仙

## CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 簡明綜合財務狀況表

As at 30 September 2021

於2021年9月30日

			<b>30 September</b>	31 March
			<b>9月30日</b>	3月31日
			<b>2021</b>	2021
		Notes	<b>HK\$'000</b>	HK\$'000
		附註	千港元	千港元
			<b>(Unaudited)</b>	(Audited)
			(未經審核)	(經審核)
<b>NON-CURRENT ASSETS</b>	<b>非流動資產</b>			
Property, plant and equipment	物業、廠房及設備	10	<b>39,958</b>	34,498
Right-of-use assets	使用權資產		<b>112,251</b>	42,719
Goodwill	商譽		<b>4,305</b>	4,305
Prepayments, other receivables and other assets	預付款項、其他應收賬款及其他資產		<b>35,666</b>	5,820
Deferred tax assets	遞延稅項資產		<b>3,387</b>	6,815
Total non-current assets	非流動資產總值		<b>195,567</b>	94,157
<b>CURRENT ASSETS</b>	<b>流動資產</b>			
Inventories	存貨		<b>33,142</b>	14,154
Trade receivables	貿易應收賬款	11	<b>37,810</b>	16,263
Prepayments, other receivables and other assets	預付款項、其他應收賬款及其他資產		<b>42,666</b>	24,966
Tax recoverable	可收回稅項		<b>3,476</b>	3,476
Pledged time deposits	已抵押定期存款		<b>57,420</b>	57,346
Cash and cash equivalents	現金及現金等價物		<b>112,338</b>	161,773
Total current assets	流動資產總值		<b>286,852</b>	277,978
<b>CURRENT LIABILITIES</b>	<b>流動負債</b>			
Trade payables	貿易應付賬款	12	<b>8,298</b>	2,076
Other payables and accruals	其他應付賬款及應計費用		<b>11,094</b>	6,616
Contract liabilities and deferred revenue	合約負債及遞延收益		<b>138,173</b>	168,182
Provision for reinstatement costs	修復成本撥備		<b>483</b>	483
Lease liabilities	租賃負債		<b>30,155</b>	16,948
Tax payable	應付稅項		<b>3,221</b>	-
Total current liabilities	流動負債總值		<b>191,424</b>	194,305

**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION** (Continued)  
**簡明綜合財務狀況表** (續)

As at 30 September 2021

於2021年9月30日

			<b>30 September</b> <b>9月30日</b> <b>2021</b> <b>HK\$'000</b> 千港元 <b>(Unaudited)</b> (未經審核)	31 March 3月31日 2021 HK\$'000 千港元 (Audited) (經審核)
		Notes 附註		
<b>NET CURRENT ASSETS</b>	流動資產淨值		<b>95,428</b>	83,673
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>	資產總值減流動負債		<b>290,995</b>	177,830
<b>NON-CURRENT LIABILITIES</b>	非流動負債			
Deferred tax liabilities	遞延稅項負債		<b>1,604</b>	1,604
Provision for reinstatement costs	修復成本撥備		<b>9,584</b>	5,114
Lease liabilities	租賃負債		<b>80,188</b>	25,538
Total non-current liabilities	非流動負債總值		<b>91,376</b>	32,256
Net assets	資產淨值		<b>199,619</b>	145,574
<b>EQUITY</b>	權益			
Issued capital	已發行股本	13	<b>4,000</b>	4,000
Reserves	儲備		<b>195,619</b>	141,574
Total equity	權益總值		<b>199,619</b>	145,574



## CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 簡明綜合權益變動表

For the six months ended 30 September 2021

截至2021年9月30日止六個月

		Issued capital 已發行 股本 HK\$'000 千港元	Share premium account 溢價賬 HK\$'000 千港元	Merger reserve 合併儲備 HK\$'000 千港元	Exchange reserve 匯兌儲備 HK\$'000 千港元	Retained profits 保留溢利 HK\$'000 千港元	Total equity 權益總值 HK\$'000 千港元
At 1 April 2020 (Audited)	於2020年4月1日(經審核)	4,000	67,788	4,995	-	81,448	158,231
Loss for the period	期內虧損	-	-	-	-	(6,189)	(6,189)
Other comprehensive income for the period	期內其他全面收入	-	-	-	30	-	30
Total comprehensive loss for the period	期內全面虧損總額	-	-	-	30	(6,189)	(6,159)
At 30 September 2020 (Unaudited)	於2020年9月30日 (未經審核)	4,000	67,788	4,995	30	75,259	152,072
At 1 April 2021 (Audited)	於2021年4月1日(經審核)	<b>4,000</b>	<b>67,788</b>	-	(4)	<b>73,790</b>	<b>145,574</b>
Profit for the period	期內溢利	-	-	-	-	<b>53,919</b>	<b>53,919</b>
Other comprehensive income for the period	期內其他全面收入	-	-	-	<b>126</b>	-	<b>126</b>
Total comprehensive income for the period	期內全面收入總額	-	-	-	<b>126</b>	<b>53,919</b>	<b>54,045</b>
At 30 September 2021 (Unaudited)	於2021年9月30日 (未經審核)	<b>4,000</b>	<b>67,788</b>	-	<b>122</b>	<b>127,709</b>	<b>199,619</b>

## CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

### 簡明綜合現金流量表

For the six months ended 30 September 2021

截至2021年9月30日止六個月

		Six months ended 30 September 截至9月30日止六個月	
		2021 HK\$'000 千港元 (Unaudited) (未經審核)	2020 HK\$'000 千港元 (Unaudited) (未經審核)
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>	<b>經營活動的現金流量</b>		
Profit/(loss) before tax	除稅前溢利/(虧損)	60,567	(7,647)
Adjustments for:	就下列各項調整：		
Depreciation of property, plant and equipment	物業、廠房及設備折舊	7,342	6,398
Depreciation of right-of-use assets	使用權資產折舊	13,196	9,359
Interest income	利息收入	(302)	(1,743)
Finance costs	財務成本	1,177	980
Loss on disposal/write-off of items of property, plant and equipment	出售/撇銷物業、廠房及設備項目虧損	3	3
Impairment/(reversal of impairment) of trade receivables, net	貿易應收賬款減值/(減值撥回)淨額	169	22
Termination of a lease	租賃終止	-	(11)
		<b>82,152</b>	7,358
Increase in inventories	存貨增加	(18,988)	(19)
Increase in trade receivables	貿易應收賬款增加	(21,716)	(6,072)
Increase in prepayments, other receivables and other assets	預付款項、其他應收賬款及其他資產增加	(47,662)	(194)
Increase in trade payables	貿易應付賬款增加	6,222	27
Increase in other payables and accruals	其他應付賬款及應計費用增加	4,478	1,667
(Decrease)/increase in contract liabilities and deferred revenue	合約負債及遞延收益(減少)/增加	(30,009)	14,724
Increase in pledged time deposits	已抵押定期存款增加	(74)	(2)
Cash (used in) generated from operations	經營業務(所用)所產生的現金	(25,597)	17,489
Interest received	已收取利息	299	1,320
Interest paid	已付利息	(1,177)	(980)
Hong Kong profits tax refunded, net	退回香港利得稅淨額	1	-
Net cash flows (used in) from operating activities	經營活動(所用)所產生的現金流量淨額	<b>(26,474)</b>	17,829

## CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Continued)

### 簡明綜合現金流量表(續)

For the six months ended 30 September 2021

截至2021年9月30日止六個月

		Six months ended 30 September 截至9月30日止六個月	
		2021 HK\$'000 千港元 (Unaudited) (未經審核)	2020 HK\$'000 千港元 (Unaudited) (未經審核)
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b> 投資活動的現金流量			
Purchases of items of property, plant and equipment	購買物業、廠房及設備項目	(8,215)	(2,914)
Deposits paid for the purchases of items of property, plant and equipment	購買物業、廠房及設備項目的已付按金	-	(148)
Decrease/(increase) in non-pledged time deposits with original maturity of more than three months when acquired	於購入時原到期日超過三個月之無抵押定期存款減少/(增加)	4,128	17,718
Net cash flows (used in)/from investing activities	投資活動(所用)/所得的現金流量淨額	(4,087)	14,656
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b> 融資活動的現金流量			
Principal portion of lease payments	租賃付款的本金部分	(14,871)	(8,636)
<b>NET INCREASE IN CASH AND CASH EQUIVALENTS</b> 現金及現金等價物增加淨額		(45,432)	23,849
Cash and cash equivalents at beginning of period	期初之現金及現金等價物	147,645	85,574
Effect of foreign exchange rate changes, net	外匯匯率變動影響淨額	125	30
<b>CASH AND CASH EQUIVALENTS AT END OF PERIOD</b>	<b>期末之現金及現金等價物</b>	<b>102,338</b>	109,453
<b>ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</b> 現金及現金等價物結餘之分析			
Cash and bank balances	現金及銀行結餘	27,236	19,060
Non-pledged time deposits with original maturity of three months or less when acquired	於購入時原到期日不超過三個月之無抵押定期存款	75,102	90,393
Non-pledged time deposits with original maturity of more than three months when acquired	於購入時原到期日超過三個月之無抵押定期存款	10,000	54,035
Cash and cash equivalents as stated in the condensed consolidated statement of financial position	簡明綜合財務狀況表所列現金及現金等價物	112,338	163,488
Non-pledged time deposits with original maturity of more than three months when acquired	於購入時原到期日超過三個月之無抵押定期存款	(10,000)	(54,035)
Cash and cash equivalents as stated in the condensed consolidated statement of cash flows	簡明綜合現金流量表所列現金及現金等價物	102,338	109,453

## NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

### 簡明綜合財務報表附註

#### 1. General Information

The Company is an exempted company with limited liability incorporated in the Cayman Islands. The registered office address of the Company is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands. The principal place of business of the Company is located at 18/F, Nan Fung Tower, 88 Connaught Road Central, Central, Hong Kong.

The Company is an investment holding company and the Company's subsidiaries were principally engaged in the provision of medical aesthetic services and the sale of skin care products.

#### 2. Basis of Preparation

The condensed consolidated financial statements have been prepared in accordance with the Hong Kong Accounting Standard ("HKAS") 34 *Interim Financial Reporting* issued by the Hong Kong Institute of Certified Public Accountants and with the applicable disclosure requirements of Appendix 16 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

The condensed consolidated financial statements does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual report for the year ended 31 March 2021.

The condensed consolidated financial statements for the six months ended 30 September 2021 have not been audited, but have been reviewed by the audit committee of the Company.

#### 1. 一般資料

本公司為一間在開曼群島註冊成立的獲豁免有限公司。本公司的註冊辦事處地址為 Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands。本公司的主要營業地點位於香港中環干諾道中88號南豐大廈18樓。

本公司為投資控股公司，而本公司附屬公司主要從事提供醫學美容服務及出售護膚產品。

#### 2. 編製基準

簡明綜合財務報表乃根據香港會計師公會頒佈的香港會計準則(「香港會計準則」)第34號中期財務報告以及香港聯合交易所有限公司證券上市規則(「上市規則」)附錄16的適用披露規定編製。

簡明綜合財務報表並不包括年度財務報表所需的所有資料及披露，並應連同本集團截至2021年3月31日止年度的年報一併閱讀。

截至2021年9月30日止六個月的簡明綜合財務報表未經審核，但已由本公司的審核委員會審閱。

### 3. Changes in Accounting Policies and Disclosures

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 March 2021, except for the followings.

#### Amendments of accounting standards adopted by the Group

The Group adopted the following revised Hong Kong Financial Reporting Standards ("HKFRSs") for the first time for the current period's financial information.

Amendments to HKFRS 9, *Interest Rate Benchmark Reform*  
HKAS 39, HKFRS 7, — *Phase 2*  
HKFRS 4 and HKFRS 16

Amendment to HKFRS 16 *Covid-19-Related Rent Concessions beyond 30 June 2021 (early adopted)*

The nature and impact of the revised HKFRSs are described below:

- (a) Amendments to HKFRS 9, HKAS 39, HKFRS 7, HKFRS 4 and HKFRS 16 address issues not dealt with in the previous amendments which affect financial reporting when an existing interest rate benchmark is replaced with an alternative risk-free rate ("RFR"). The phase 2 amendments provide a practical expedient to allow the effective interest rate to be updated without adjusting the carrying amount of financial assets and liabilities when accounting for changes in the basis for determining the contractual cash flows of financial assets and liabilities, if the change is a direct consequence of the interest rate benchmark reform and the new basis for determining the contractual cash flows is economically equivalent to the previous basis immediately preceding the change. In addition, the amendments permit changes required by the interest rate benchmark reform to be made to hedge designations and hedge documentation without the hedging relationship being discontinued. Any gains or losses that could arise on transition are dealt with through the normal requirements of HKFRS 9 to measure and recognise hedge ineffectiveness. The amendments also provide a temporary relief to entities from having to meet the separately identifiable requirement when an RFR is designated as a risk component. The relief allows an entity, upon designation of the hedge, to assume that the separately identifiable requirement is met, provided the entity reasonably expects the RFR risk component to become separately identifiable within the next 24 months. Furthermore, the amendments require an entity to disclose additional information to enable users of financial statements to understand the effect of interest rate benchmark reform on an entity's financial instruments and risk management strategy. The amendment did not have any impact on the financial position and performance of the Group.

### 3. 會計政策及披露之變動

編製中期簡明綜合財務資料時所採納的會計政策與編製本集團截至2021年3月31日止年度的年度綜合財務報表時所應用者一致，惟以下各項除外。

#### 本集團所採納的會計準則修訂

本集團於本期間的財務資料內首次採納以下經修訂香港財務報告準則（「香港財務報告準則」）。

香港財務報告準則第9號、*利率基準改革*  
香港會計準則第39號、*— 第2階段*  
香港財務報告準則第7號、  
香港財務報告準則第4號及  
香港財務報告準則第16號修訂

香港財務報告準則第16號修訂 *2021年6月30日*  
*後與新冠肺炎*  
*有關的租金*  
*減免 (提早*  
*採納)*

經修訂香港財務報告準則的性質及影響載述如下：

- (a) 當現有利率基準被可替代無風險利率（「無風險利率」）替代時，香港財務報告準則第9號、香港會計準則第39號、香港財務報告準則第7號、香港財務報告準則第4號及香港財務報告準則第16號修訂解決先前影響財務報告的修訂未處理的問題。第2階段修訂提供對於釐定金融資產及負債的合約現金流量的基準的變動進行會計處理時無需調整金融資產及負債的賬面值而更新實際利率的可行權宜方法，前提為該變動為利率基準改革的直接後果且釐定合約現金流量的新基準於經濟上等同於緊接變動前的先前基準。此外，該等修訂允許利率基準改革所規定對沖指定及對沖文件進行更改，而不會中斷對沖關係。過渡期間可能產生的任何損益均通過香港財務報告準則第9號的正常規定進行處理，以計量及確認對沖無效性。倘無風險利率被指定為風險組成部分，該等修訂亦暫時寬免實體必須滿足可單獨識別的要求。倘實體合理地預期無風險利率風險組成部分於未來24個月內將變得可單獨識別，則該寬免允許實體於指定對沖後假定已滿足可單獨識別的規定。此外，該等修訂亦規定實體須披露額外資料，以使財務報表的使用者能夠瞭解利率基準改革對實體的金融工具及風險管理策略的影響。該修訂對本集團的財務狀況及表現並無任何影響。

### 3. Changes in Accounting Policies and Disclosures (Continued)

#### Amendments of accounting standards adopted by the Group (Continued)

- (b) Amendment to HKFRS 16 issued in April 2021 extends the availability of the practical expedient for lessees to elect not to apply lease modification accounting for rent concessions arising as a direct consequence of the covid-19 pandemic by 12 months. Accordingly, the practical expedient applies to rent concessions for which any reduction in lease payments affects only payments originally due on or before 30 June 2022, provided the other conditions for applying the practical expedient are met. The amendment is effective retrospectively for annual periods beginning on or after 1 April 2021 with any cumulative effect of initially applying the amendment recognised as an adjustment to the opening balance of retained profits at the beginning of the current accounting period. Earlier application is permitted.

The Group has early adopted the amendment on 1 April 2021 and applied the practical expedient during the period ended 30 September 2021 to all rent concessions granted by the lessors that affected only payments originally due on or before 30 June 2022 as a direct consequence of the covid-19 pandemic.

### 4. Revenue, Other Income and Operating Segment Information

An analysis of revenue is as follow:

		<b>Six months ended</b>	
		<b>30 September</b>	
		截至9月30日止六個月	
		<b>2021</b>	2020
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
		<b>(Unaudited)</b>	(Unaudited)
		(未經審核)	(未經審核)
<b>Revenue from contracts with customers</b>	<b>客戶合約收益</b>		
Treatment services	療程服務	<b>176,594</b>	50,566
Skin care products	護膚產品	<b>22,775</b>	3,657
Medical consultation services	醫療諮詢服務	<b>13</b>	14
Prescription and dispensing of medical products	醫療產品處方及配藥	<b>348</b>	263
		<b>199,730</b>	54,500

### 3. 會計政策及披露之變動(續)

#### 本集團所採納的會計準則修訂(續)

- (b) 於2021年4月頒佈的香港財務報告準則第16號修訂將承租人選擇不對新冠肺炎疫情直接導致的租金減免應用租賃修訂會計處理的權宜方法的可使用期間延長12個月。因此，該權宜方法可應用於任何租賃付款扣減僅影響原先於2022年6月30日或之前到期的付款的情況，惟須符合應用該權宜方法的其他條件。該修訂對2021年4月1日或之後開始的年度期間以追溯方式生效，首次應用該修訂的任何累計影響應以對當前會計期間開始時保留溢利的期初結餘作出調整的方式予以確認，並允許提早應用。

本集團已於2021年4月1日提早採納該修訂，並於截至2021年9月30日止期間就出租人所授出僅影響原先於2022年6月30日或之前到期的付款的所有新冠肺炎疫情直接導致的租金減免應用可行權宜方法。

### 4. 收益、其他收入及營運分部資料

收益分析如下：

4. Revenue, Other Income and Operating Segment Information (Continued)

Revenue from contracts with customers

(i) Disaggregated revenue information

For the six months ended 30 September 2021 and 2020

4. 收益、其他收入及營運分部資料(續)

客戶合約收益

(i) 分拆收益資料

截至2021年及2020年9月30日止六個月

		<b>Six months ended 30 September</b>	
		截至9月30日止六個月	
		<b>2021</b>	2020
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
<b>Types of goods or services</b>	<b>貨品或服務種類</b>		
Sale of skin care products	銷售護膚產品	22,775	3,657
Provision of medical aesthetic services	提供醫學美容服務	176,955	50,843
Total revenue from contracts with customers	客戶合約總收益	<b>199,730</b>	54,500
<b>Geographical markets</b>	<b>地域市場</b>		
Hong Kong	香港	195,358	54,500
The PRC	中國	4,372	-
Total revenue from contracts with customers	客戶合約總收益	<b>199,730</b>	54,500
<b>Timing of revenue recognition</b>	<b>收益確認時間</b>		
Goods or services transferred at a point in time	在某時點轉讓貨品或服務	23,135	3,934
Services transferred over time	按時間轉讓服務	176,595	50,566
Total revenue from contracts with customers	客戶合約總收益	<b>199,730</b>	54,500

The following table shows the amounts of revenue recognised in the current reporting period that were included in the contract liabilities at the beginning of the reporting period:

下表顯示本報告期確認的收益金額，有關金額計入報告期初的合約負債：

		<b>Six months ended 30 September</b>	
		截至9月30日止六個月	
		<b>2021</b>	2020
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
Revenue recognised that was included in contract liabilities at the beginning of the reporting period:	計入報告期初合約負債的已確認收益：		
Treatment services	療程服務	112,550	27,821
Skin care products	護膚產品	32	34
		<b>112,582</b>	27,855



4. Revenue, Other Income and Operating Segment Information (Continued)

**Revenue from contracts with customers** (Continued)

**(ii) Performance obligations**

Information about the Group's performance obligations is summarised below:

*Provision of medical aesthetic services*

The performance obligation associated with treatment services is satisfied over time when the services are rendered. The performance obligations associated with medical consultation services and prescription and dispensing of medical products are satisfied at the point in time when the services are rendered.

*Sale of skin care products*

The performance obligation is satisfied upon delivery of the skin care products and payment is mainly on cash and/or credit card settlement, except for corporate customers, where payment is due within 2 to 30 days from delivery.

An analysis of other income is as follow:

		<b>Six months ended</b>	
		<b>30 September</b>	
		截至9月30日止六個月	
		<b>2021</b>	2020
Note		<b>HK\$'000</b>	HK\$'000
附註		千港元	千港元
		<b>(Unaudited)</b>	(Unaudited)
		(未經審核)	(未經審核)
<b>Other income</b>	<b>其他收入</b>		
Bank interest income	銀行利息收入	<b>302</b>	1,743
Government grants	政府補助	(a) <b>–</b>	5,596
Others	其他	<b>122</b>	67
		<b>424</b>	7,406

(a) The government subsidies for the six months ended 30 September 2020 represented subsidies received under the Employment Support Scheme and the applicable subsidy scheme under the Anti-epidemic Fund of the Government of Hong Kong Special Administrative Region. There were no unfulfilled conditions or contingencies relating to the subsidies.

4. 收益、其他收入及營運分部資料(續)

**客戶合約收益**(續)

**(ii) 履約責任**

有關本集團履約責任的資料概述如下：

*提供醫學美容服務*

與療程服務有關的履約責任於服務已提供時隨時間達成。與醫療諮詢服務以及醫療產品處方及配藥有關的履約責任於提供服務的某一時間點達成。

*銷售護膚產品*

履約責任於交付護膚產品後達成，而付款乃主要以現金及／或信用卡結算，惟付款於交付起計2至30日內到期的企業客戶除外。

其他收入分析如下：

(a) 截至2020年9月30日止六個月的政府補助指收取香港特別行政區政府的「保就業」計劃及「防疫抗疫基金」下的適用資助計劃的補助。有關該等補助概無任何未達成的條件或或然情況。



5. Profit/(Loss) before Tax

The Group's profit/(loss) before tax is arrived at after charging/(crediting):

5. 除稅前溢利／(虧損)

本集團除稅前溢利／(虧損)乃經扣除／(計入)下列各項後得出：

		<b>Six months ended</b>	
		<b>30 September</b>	
		截至9月30日止六個月	
		<b>2021</b>	2020
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
		<b>(Unaudited)</b>	(Unaudited)
		(未經審核)	(未經審核)
Lease payments not included in the measurement of lease liabilities	不計入租賃負債計量的租賃付款	<b>701</b>	362
Employee benefit expenses (excluding Directors' remuneration):	僱員福利開支 (不包括董事酬金):		
Salaries, bonuses and other allowances	薪金、花紅及其他津貼	<b>50,141</b>	28,276
Retirement benefit scheme contributions (defined contribution scheme)	退休福利計劃供款 (定額供款計劃)	<b>2,004</b>	946
		<b>52,145</b>	29,222
Auditor's remuneration	核數師酬金	<b>1,032</b>	1,253
Depreciation of property, plant and equipment	物業、廠房及設備折舊	<b>7,342</b>	6,398
Depreciation of right-of-use assets	使用權資產折舊	<b>13,196</b>	9,359
Impairment of trade receivables, net	貿易應收賬款減值淨額	<b>169</b>	22
Foreign exchange differences, net	外匯差額淨額	<b>(243)</b>	123

## 6. Finance costs

## 6. 財務成本

		<b>Six months ended</b>	
		<b>30 September</b>	
		截至9月30日止六個月	
		<b>2021</b>	2020
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
		<b>(Unaudited)</b>	(Unaudited)
		(未經審核)	(未經審核)
Interest on lease liabilities	租賃負債利息	<b>1,177</b>	980

## 7. Income Tax Expense/(Credit)

Hong Kong profits tax has been provided at a rate of 16.5% (six months ended 30 September 2020: 16.5%) on the estimated assessable profits in Hong Kong during the period.

## 7. 所得稅開支／(抵免)

期內，香港利得稅已按於香港產生的估計應課稅溢利的16.5%（截至2020年9月30日止六個月：16.5%）稅率作出撥備。

		<b>Six months ended</b>	
		<b>30 September</b>	
		截至9月30日止六個月	
		<b>2021</b>	2020
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
		<b>(Unaudited)</b>	(Unaudited)
		(未經審核)	(未經審核)
Current	即期		
— Charge for the period	— 期內支出	<b>3,220</b>	295
Deferred tax	遞延稅項	<b>3,428</b>	(1,753)
Total tax charge/(credit) for the period	期內稅項支出／(抵免)總額	<b>6,648</b>	(1,458)

## 8. Dividends

The Board does not recommend the payment of an interim dividend for the six months ended 30 September 2021 (six months ended 30 September 2020: Nil).

## 8. 股息

董事會不建議就截至2021年9月30日止六個月派付中期股息（截至2020年9月30日止六個月：零）。

9. Earnings/(Loss) Per Share Attributable to Ordinary Equity Holders of the Company

The calculation of basic earnings/(loss) per share is based on:

9. 本公司普通股權益持有人應佔每股盈利／(虧損)

每股基本盈利／(虧損)乃按以下數據計算：

		<b>Six months ended</b>	
		<b>30 September</b>	
		截至9月30日止六個月	
		<b>2021</b>	2020
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
		<b>(Unaudited)</b>	(Unaudited)
		(未經審核)	(未經審核)
<b>Earnings/(loss):</b>	<b>盈利／(虧損)：</b>		
Profit/(loss) attributable to ordinary equity holders of the Company	本公司普通股權益持有人應佔溢利／(虧損)	<b>53,919</b>	(6,189)
		<b>'000</b>	'000
		千股	千股
<b>Number of shares:</b>	<b>股份數目：</b>		
Weighted average number of ordinary shares in issue used in the basic earnings/(loss) per share calculation	已發行普通股的加權平均數，用作計算每股基本盈利／(虧損)	<b>400,000</b>	400,000

No adjustment has been made to the basic earnings/(loss) per share presented as the Group had no potentially dilutive ordinary shares in issue during those periods.

由於本集團於該等期間並無潛在攤薄性已發行普通股，故並無對所呈列每股基本盈利／(虧損)作出調整。

10. Property, Plant and Equipment

During the six months ended 30 September 2021, the Group acquired property, plant and equipment of approximately HK\$12,717,000 (six months ended 30 September 2020: HK\$2,914,000).

10. 物業、廠房及設備

截至2021年9月30日止六個月，本集團收購物業、廠房及設備約12,717,000港元(截至2020年9月30日止六個月：2,914,000港元)。

## 11. Trade Receivables

## 11. 貿易應收賬款

		<b>30 September</b>	31 March
		9月30日	3月31日
		<b>2021</b>	2021
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
		<b>(Unaudited)</b>	(Audited)
		(未經審核)	(經審核)
Credit card receivables	信用卡應收賬款	<b>37,748</b>	16,344
Others	其他	<b>359</b>	47
		<b>38,107</b>	16,391
Impairment	減值	<b>(297)</b>	(128)
		<b>37,810</b>	16,263

The Group's trading terms with its clients are mainly on cash and/or credit card settlement while the trading terms with its corporate customers are on credit. The credit period is generally 2 to 30 days for credit card settlement for the respective financial institutions and up to 60 days for corporate customers. The Group seeks to maintain strict control over its outstanding receivables to minimise credit risk. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

An ageing analysis of the trade receivables as at the end of the reported period, based on the invoice date and net of loss allowance, is as follow:

本集團與其客戶的交易條款主要為現金及／或信用卡結算，而與其企業客戶的交易條款為信貸結算。與各金融機構以信用卡結算的信貸期一般為2至30日，而與企業客戶的信貸期最多為60日。本集團致力嚴格監控其未收取的應收賬款，以盡量降低信貸風險。高級管理層定期審閱逾期結餘。本集團並無就其貿易應收賬款結餘持有任何抵押品或其他信貸加強措施。貿易應收賬款為免息。

於報告期末，貿易應收賬款按發票日期及經扣除虧損撥備的賬齡分析如下：

		<b>30 September</b>	31 March
		9月30日	3月31日
		<b>2021</b>	2021
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
		<b>(Unaudited)</b>	(Audited)
		(未經審核)	(經審核)
Within 1 month	一個月內	<b>19,932</b>	15,559
1 to 3 months	一至三個月	<b>17,715</b>	669
Over 3 months	三個月以上	<b>163</b>	35
		<b>37,810</b>	16,263

## 11. Trade Receivables (Continued)

An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on days past due for groupings of various customer segments with similar loss patterns (i.e., by customer type). The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Generally, trade receivables are written off if past due for more than one year and are not subject to enforcement activity.

Set out below is the information about the credit risk exposure on the Group's trade receivables using a provision matrix:

### As at 30 September 2021

		Current 即期	Past due 逾期		Total 總計
			1 to 3 months 一至三個月	Over 3 months 三個月以上	
Expected credit loss rate	預期信貸虧損率	0.82%	0.76%	3.50%	0.78%
Gross carrying amount (HK\$'000)	總賬面值(千港元)	3,697	34,240	170	38,107
Expected credit losses (HK\$'000)	預期信貸虧損(千港元)	30	261	6	297

### As at 31 March 2021

		Current 即期	Past due 逾期		Total 總計
			1 to 3 months 一至三個月	Over 3 months 三個月以上	
Expected credit loss rate	預期信貸虧損率	0.77%	0.99%	2.78%	0.78%
Gross carrying amount (HK\$'000)	總賬面值(千港元)	16,153	202	36	16,391
Expected credit losses (HK\$'000)	預期信貸虧損(千港元)	125	2	1	128

## 11. 貿易應收賬款(續)

於各報告日期均採用撥備矩陣進行減值分析，以計量預期信貸虧損。撥備率乃基於就擁有類似虧損模式的多個客戶分部進行分組(即按客戶類別)而逾期的日數計算。該計算反映或然率加權結果、貨幣時值及於報告日期可得的有關過往事件、當前條件及未來經濟條件預測的合理及具支持性資料。一般而言，倘貿易應收賬款逾期超過一年，則予以撇銷，且不受執行工作規限。

下表載列就本集團貿易應收賬款使用撥備矩陣的信貸風險的資料：

### 於 2021 年 9 月 30 日

		Current 即期	Past due 逾期		Total 總計
			1 to 3 months 一至三個月	Over 3 months 三個月以上	

### 於 2021 年 3 月 31 日

		Current 即期	Past due 逾期		Total 總計
			1 to 3 months 一至三個月	Over 3 months 三個月以上	

## 12. Trade Payables

## 12. 貿易應付賬款

		<b>30 September</b>	31 March
		<b>9月30日</b>	3月31日
		<b>2021</b>	2021
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
		<b>(Unaudited)</b>	(Audited)
		(未經審核)	(經審核)
Third party suppliers	第三方供應商	<b>8,298</b>	2,076

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follow:

於報告期末，貿易應付賬款按發票日期的賬齡分析如下：

		<b>30 September</b>	31 March
		<b>9月30日</b>	3月31日
		<b>2021</b>	2021
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
		<b>(Unaudited)</b>	(Audited)
		(未經審核)	(經審核)
Within 1 month	一個月內	<b>8,298</b>	2,076

The trade payables are non-interest-bearing and generally have an average settlement term of 30 days.

貿易應付賬款為免息，平均結算期一般為30日。

### 13. Share Capital Shares

### 13. 股本 股份

		<b>30 September</b>	31 March
		<b>9月30日</b>	3月31日
		<b>2021</b>	2021
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
		<b>(Unaudited)</b>	(Audited)
		(未經審核)	(經審核)
Authorised:	法定：		
2,000,000,000 ordinary shares of HK\$0.01 each	2,000,000,000股每股面值 0.01港元的普通股	<b>20,000</b>	20,000
Issued and fully paid:	已發行及繳足：		
400,000,000 ordinary shares of HK\$0.01 each	400,000,000股每股面值 0.01港元的普通股	<b>4,000</b>	4,000

#### Share options

Details of the Company's share option scheme are included in note 14 to the financial statements.

#### 購股權

本公司購股權計劃的詳情載於財務報表附註14。

### 14. Share Option Scheme

The Company operates a share option scheme (the "Scheme") for the purpose of attracting and retaining the best available personnel, providing additional incentive to eligible participants, and promoting the success of the business of the Group.

Eligible participants of the Scheme include the Company's Directors, including independent non-executive directors, other employees of the Group, and any consultants, advisers, distributors, contractors, suppliers, agents, customers, business partners and service providers of any member of the Group. The Scheme was approved and adopted by the shareholders of the Company on 19 December 2016 and, unless otherwise cancelled or amended, will remain in force for 10 years from that date.

At the date of approval of these financial statements, the maximum number of shares available for issue was 40,000,000, representing 10% of the shares of the Company in issue.

### 14. 購股權計劃

本公司制訂一項購股權計劃(「該計劃」)，旨在吸引及挽留最稱職人員，並向本集團合資格參與者提供額外獎勵以及推動本集團業務創出佳績。

該計劃之合資格參與者包括本公司董事(包括獨立非執行董事、本集團其他僱員、本集團任何成員公司的任何諮詢人士、顧問、分銷商、承包商、供應商、代理、客戶、商業夥伴及服務供應商)。該計劃已於2016年12月19日獲本公司股東批准及採納，而除另有撤銷或修訂外，該計劃將由該日起計十年內仍具效力。

於該等財務報表獲批准之日，最高可發行之股份數目為40,000,000股，佔本公司已發行股份的10%。

#### 14. Share Option Scheme (Continued)

The maximum number of shares issued and to be issued upon exercise of options granted under the Scheme and any other share option scheme of the Company to each participant in any 12-month period up to the date of grant shall not exceed 1% of the total shares of the Company in issue.

An option may be exercised in accordance with the terms of the Scheme at any time during a period commencing on such date on or after the date on which the option is granted as the Directors may determine in granting the option and expiring at the close of business on such date as the Directors may determine in granting the option but in any event shall not exceed 10 years from the date of grant (which is the date of offer of grant if the offer for the grant of the option is accepted).

An offer for the grant of options must be accepted within 7 days inclusive of the day on which such offer was made. The amount payable on acceptance of the offer for the grant of an option is HK\$1.0.

The exercise price of share options is determinable by the Directors provided always that it shall be at least the higher of (i) the closing price of the Company's shares as stated in The Stock Exchange of Hong Kong Limited (the "Stock Exchange")'s daily quotations sheet on the date of offer; (ii) the average of the closing prices of the Company's shares as stated in the Stock Exchange's daily quotations sheets for the 5 trading days immediately preceding the date of offer; and (iii) the nominal value of a share of the Company.

Share options do not confer rights on the holders to dividends or to vote at shareholders' meeting.

#### 14. 購股權計劃(續)

每位參與者自任何12個月期間直至授出日期，根據該計劃及本公司任何其他購股權計劃獲授之購股權獲行使時，已發行及將予發行之股份數目上限不得超過本公司已發行股份總數之1%。

購股權可根據該計劃之條款，於董事授出購股權時可能釐定授出購股權當日或之後的有關日期開始之期間內任何時間行使，並於董事授出購股權時可能釐定之有關日期營業時間結束時屆滿，惟於任何情況下，由授出日期(倘授出購股權之要約獲接納，即為授出購股權要約當日)起計不得超過十年。

授出購股權的要約須於提出有關要約日期(包括當日)起七日內接納。接納要約時就獲授一份購股權的應付金額為1.0港元。

購股權之行使價乃由董事釐定，惟其有關行使價須至少為以下較高者：(i)本公司股份於要約日期在香港聯合交易所有限公司(「聯交所」)每日報價表所列之收市價；(ii)本公司股份於緊接要約日期前五個交易日在聯交所每日報價表所列之平均收市價；及(iii)本公司每股股份之面值。

購股權持有人無權收取股息或在股東大會上投票之權利。



## 15. Related Party Transactions

- (a) In addition to the transactions detailed elsewhere in these financial statements, the Group had the following transactions with related parties during the period:

		<b>Six months ended 30 September</b>	
		截至9月30日止六個月	
		<b>2021</b>	2020
Note		<b>HK\$'000</b>	HK\$'000
附註		千港元	千港元
		<b>(Unaudited)</b>	(Unaudited)
		(未經審核)	(未經審核)
	Consultancy fees paid to a director 支付予董事的諮詢費用	<b>300</b>	50

- (i) The fees were paid for the medical advisory services provided by Dr. LAM Ping Yan, an executive director of the Company. The fees were charged pursuant to the terms in the consultancy agreement.
- (b) Compensation of key management personnel of the Group, including Directors' remuneration, is as follow:

## 15. 關連方交易

- (a) 除該等財務報表其他部分所詳述的交易外，本集團於期內與關連方有以下交易：

		<b>Six months ended 30 September</b>	
		截至9月30日止六個月	
		<b>2021</b>	2020
Note		<b>HK\$'000</b>	HK\$'000
附註		千港元	千港元
		<b>(Unaudited)</b>	(Unaudited)
		(未經審核)	(未經審核)

- (i) 該等費用乃就本公司執行董事林秉恩醫生提供的醫療顧問服務而支付。該等費用乃根據諮詢協議的條款收取。

- (b) 本集團主要管理人員的薪金(包括董事薪酬)如下：

		<b>Six months ended 30 September</b>	
		截至9月30日止六個月	
		<b>2021</b>	2020
		<b>HK\$'000</b>	HK\$'000
		千港元	千港元
		<b>(Unaudited)</b>	(Unaudited)
		(未經審核)	(未經審核)
	Fees 袍金	<b>300</b>	50
	Short term employee benefits 短期僱員福利	<b>3,900</b>	3,179
	Post-employment benefits 離職後福利	<b>18</b>	18
		<b>4,218</b>	3,247

## 16. Notes to the Condensed Consolidated Statement of Cash Flows

During the six months ended 30 September 2021, the Group entered into rental agreements in respect of its office premises under operating leases. Pursuant to the terms and conditions of the rental agreements, the Group is required to restore the sites to the conditions as stipulated in the rental agreements. Accordingly, the Group had accrued and capitalised the estimated restoration costs of approximately HK\$50,000 (six months ended 30 September 2020: approximately HK\$50,000) when such obligations arose.

## 17. Capital commitments

The Group had the following capital commitments at the end of the reporting period:

## 16. 簡明綜合現金流量表附註

截至2021年9月30日止六個月，本集團根據經營租賃就其辦公室物業訂立租賃協議。根據租賃協議的條款及條件，本集團須將該等場所修復至租賃協議規定的狀況。因此，本集團在有關責任產生時已累計及資本化估計修復成本約50,000港元（截至2020年9月30日止六個月：約50,000港元）。

## 17. 資本承擔

本集團於報告期末有以下的資本承擔：

		<b>30 September</b> 9月30日 <b>2021</b> <b>HK\$'000</b> 千港元 <b>(Unaudited)</b> (未經審核)	31 March 3月31日 2021 HK\$'000 千港元 (Audited) (經審核)
Contracted, but not provided for:	已訂約，但未計提撥備：		
Property, plant and equipment	物業、廠房及設備	<b>13,612</b>	-

## 18. Events after the Reporting Period

On 6 October 2021, Vitae Wellness Beauty Limited, an indirect wholly-owned subsidiary of the Company, as lessee, and Golden Relay Company Limited, an independent third party, as lessor, entered into the lease agreement 2021 in respect of the lease of the entire 22th Floor of Soundwill Plaza, which shall commence from 18 October 2021 and expire on 17 October 2027 (both days inclusive). The Company plans to use this premises as medical aesthetic centre and for the sale of skin care products.

## 18. 報告期後事項

於2021年10月6日，本公司間接全資附屬公司Vitae Wellness Beauty Limited（作為承租人）與獨立第三方崇贊有限公司（作為出租人）就租賃金朝陽中心22樓全層訂立2021年租賃協議，租賃期由2021年10月18日至2027年10月17日（包括首尾兩日）屆滿。本公司計劃將該物業用作醫學美容中心及銷售護膚產品。

## MANAGEMENT DISCUSSION AND ANALYSIS

### 管理層討論及分析

#### BUSINESS REVIEW

For the six months ended 30 September 2021 (the “Period Under Review”), the Group delivered record-high revenue of HK\$199.7 million, up by HK\$145.2 million, or 266.4%, when compared with the period ended 30 September 2020 (“Previous Period”). The notable climb was mainly due to improved consumer sentiments with the COVID-19 pandemic situation contained. At the continuous marketing efforts of the Group and with help from the Consumption Voucher Scheme, sales increased significantly. As a result, the Group turned profitable for the Period Under Review with profit amounting to approximately HK\$53.9 million (Previous Period: net loss of approximately HK\$6.2 million).

The Group is currently operating three “CosMax” brand medical aesthetic centres at strategic locations in Causeway Bay, Central District and Tsim Sha Tsui. The Causeway Bay centre is in a duplex unit with an overall area of 12,156 sq. ft. and 30 treatment rooms. As for the Tsim Sha Tsui centre and Central centre, they occupy 6,050 sq. ft. and 3,092 sq. ft., and have up to 17 and 9 treatment rooms, respectively. The Group has also continuously acquired latest technologies to ensure it is able to provide superb quality services. As at 30 September 2021, the Group owned over 164 treatment devices for providing diverse treatment procedures to customers. The devices and procedures have all been clinically evaluated by doctors before being adopted to ensure customers are given safe and top quality experience. The centres, at prime locations and backed by latest advanced technologies, have allowed the Group to attract a wide range of customers and effectively build up its customer base.

The Group has unveiled a new beauty brand “VITAE” with a new collective standard called “Healthy Beauty”. Mrs. Gigi Ma, founder of the brand, emphasizes the principle of “Inner health realizes external beauty”, thus established the brand with the philosophy of balancing beauty, maintaining a perfect balance between beauty and health, and emanating beauty from within. That is what inspired the concept of VITAE-Wellness Beauty medical aesthetic services. With health awareness increasing among people, the Group believes “healthy beauty” will be the new market trend. VITAE has been launched in all CosMax centres that more customers can experience the new brand. In addition, the Group has signed two new lease agreements for open new centres at prime locations, including 10th and 11th floor in New World Tower II, 16–18 Queen’s Road Central and the entire 16th floor in the Peninsula Office Tower, 18 Middle Road, Tsim Sha Tsui, allowing it to expand business and strengthen the market shares of both CosMax and VITAE.

#### 業務回顧

截至2021年9月30日止六個月（「回顧期間」），本集團的收益錄得記錄新高199.7百萬港元，較截至2020年9月30日止期間（「過往期間」）增加145.2百萬港元或266.4%。該顯著增加主要乃由於新冠肺炎疫情得到遏制，以致消費者情緒有所改善。在本集團的持續營銷及消費券計劃的幫助下，銷售額大幅增長。因此，本集團於回顧期間扭虧為盈，溢利約為53.9百萬港元（過往期間：淨虧損約6.2百萬港元）。

本集團目前正於銅鑼灣、中環區及尖沙咀的黃金地段經營三間以「CosMax」為品牌的醫學美容中心。銅鑼灣中心為複式單位，擁有30間診療室，整體佔地面積為12,156平方呎。至於面積分別為6,050平方呎及3,092平方呎的尖沙咀中心及中環中心則分別擁有17間及9間診療室。本集團亦持續獲取最新科技，確保能夠提供頂尖優質服務。於2021年9月30日，本集團擁有超過164台療程設備，可為客戶提供多元化的療程程序。設備及程序均經醫生臨床評估後方予以採用，為客戶提供安全而優質的體驗。位於黃金地段且具備最先進技術的中心使本集團能夠吸引廣泛的客戶，並有效地建立其客戶群。

由於現今以「健康的美」為全新統一標準，本集團已推出全新美容品牌「VITAE」。品牌創立人馬黎珈而女士強調「內在的健康，成就外在的美麗」的原則成立該品牌。該品牌理念十分注重平衡美，主張維持美容與健康的完美平衡及由內而外散發出美麗光彩。此理念因而成就VITAE – Wellness Beauty輕醫美服務概念。隨著大眾的健康意識提升，本集團相信「健康的美」將成為新市場趨勢。VITAE已於所有CosMax中心推出，讓更多客戶可體驗新品牌。此外，本集團已簽訂兩份新租賃協議，以於黃金地段開設新中心，包括皇后大道中16–18號新世界大廈二座10樓及11樓以及尖沙咀中間道18號半島酒店辦公室大樓16樓全層，使其可擴大業務並提高CosMax及VITAE的市場份額。

## BUSINESS REVIEW (Continued)

Quality skin care products branded XOVĒ, a new skin care product line created by the responsible Swiss skin care research team, are offered to customers complementing treatments for delivering optimum results. Alive to the potential of online shopping, the Group has scaled up efforts to promote e-commerce. XOVĒ's e-shop was launched in July 2020, and online platforms have been established on T-mall (天貓), Xiaohongshu (小紅書) and Mini program (小程序) for selling XOVĒ products to PRC customers and broaden the Group's customer base. To reach more potential customers yet and raise public awareness, the first XOVĒ retail store opened in Mandarin Oriental Hong Kong in June 2021. The Group also collaborated with Mandarin Oriental Hong Kong and offered XOVĒ staycation packages and an exclusive "XOVĒ White Truffle Treasure Afternoon Tea" to its guests between June and August 2021.

The Group is well-prepared to capture more potential customers capitalizing on its continuous effort to seize opportunities to deepen market penetration by opening new medical aesthetic service centres and skin care products retail stores in Hong Kong in FY2022.

## FINANCIAL REVIEW

### Revenue

Revenue amounted to approximately HK\$199.7 million for the Period Under Review, representing an increase of approximately HK\$145.2 million or 266.4% as compared to approximately HK\$54.5 million for the Previous Period. The increase was primarily attributable to market recovery from the COVID-19 pandemic and the reopening of the Group's medical aesthetic centres which were subject to compulsory closure requirements implemented by the Government of Hong Kong Special Administrative Region during the Previous Period. Also, the Group has implement effective marketing promotions to increase public awareness for skin care products.

### Cost of inventories and consumables

Cost of inventories and consumables amounted to approximately HK\$13.3 million and HK\$5.6 million for the Period Under Review and Previous Period respectively, representing 6.7% and 10.3% of total revenue for the respective periods.

## 業務回顧(續)

優質護膚產品品牌XOVĒ為由瑞士皮膚科研專責團隊創建的新護膚產品系列，為客戶提供輔助療程以達到最佳效果。鑑於網上購物的潛力，本集團加大力度推動電子商務。XOVĒ網店於2020年7月開設，並在天貓、小紅書及小程序推出網上平台，向中國客戶銷售XOVĒ產品，以擴大本集團的客戶群。為吸引更多潛在客戶並提高公眾知名度，首家XOVĒ零售店於2021年6月在香港文華東方酒店開業。本集團亦與香港文華東方酒店合作，於2021年6月至8月期間向賓客提供XOVĒ住宿套票及獨家「XOVĒ白松露瑰寶下午茶」。

本集團已做好準備把握更多潛在客戶，繼續努力抓緊機遇，透過於2022財政年度在香港開設新的醫學美容服務中心及護膚產品零售店以進一步滲透市場。

## 財務回顧

### 收益

回顧期間，收益約為199.7百萬港元，較過往期間約54.5百萬港元增加約145.2百萬港元或266.4%。有關增加主要由於市場從新冠肺炎疫情中復甦，以及本集團的醫學美容中心重開，該等中心於過往期間須遵守香港特別行政區政府實施的強制關閉規定。此外，本集團已實施有效的市場推廣活動，以提高公眾對護膚產品的認識。

### 存貨及消耗品成本

回顧期間及過往期間，存貨及消耗品成本分別約為13.3百萬港元及5.6百萬港元，分別佔各期間總收益的6.7%及10.3%。

## FINANCIAL REVIEW (Continued)

### Staff costs

Staff costs increased by approximately HK\$23.7 million, or 72.5%, from approximately HK\$32.7 million for the Previous Period to approximately HK\$56.4 million for the Period Under Review. The increase was primarily attributable to the increase in commission paid to doctors and front-line staff whose incentive scheme tied to various key performance indicators such as the number of package sold or number of treatment conducted. As a result of increase in sales of packages and total revenue during the Period Under Review, commission payable to doctors and front-line staff were increased.

### Property rentals and related expenses

Property rentals and related expenses increased by approximately HK\$7.1 million or 68.3%, from approximately HK\$10.4 million for the Previous Period to approximately HK\$17.5 million for the Period Under Review. The increase was primarily due to additional offices and new medical aesthetic centres which the tenancy period started during the Period Under Review.

### Depreciation of property, plant and equipment

Depreciation expenses in relation to property, plant and equipment amounted to approximately HK\$7.3 million and approximately HK\$6.4 million for the Period Under Review and Previous Period, respectively, representing 3.7% and 11.7% of total revenue for the respective periods.

### Other expenses

Other expenses increased by approximately HK\$30.5 million or 227.6%, from approximately HK\$13.4 million for the Previous Period to approximately HK\$43.9 million for the Period Under Review. The increase was primarily attributable to increase in promotional campaigns for different marketing channels and various social media platforms and bank charges which were in line with increase in cash sales during the Period Under Review.

### Finance costs

Finance costs amounted to approximately HK\$1.2 million and approximately HK\$1.0 million for the Period Under Review and Previous Period, respectively.

## 財務回顧(續)

### 員工成本

員工成本由過往期間的約32.7百萬港元，增加約23.7百萬港元或72.5%至回顧期間的約56.4百萬港元。有關增加主要由於向醫生及前線員工支付的佣金增加，其激勵計劃與售出療程數目或進行的療程數目等不同主要表現指標掛鈎。由於回顧期間的療程銷售及總收益增加，應付醫生及前線員工的佣金增加。

### 物業租金及相關開支

物業租金及相關開支由過往期間的約10.4百萬港元，增加約7.1百萬港元或68.3%至回顧期間的約17.5百萬港元。有關增加主要由於額外辦事處及新醫學美容中心的租賃期於回顧期間內開始所致。

### 物業、廠房及設備折舊

回顧期間及過往期間，有關物業、廠房及設備的折舊開支分別約為7.3百萬港元及約6.4百萬港元，分別佔各期間總收益的3.7%及11.7%。

### 其他開支

其他開支由過往期間的約13.4百萬港元，增加約30.5百萬港元或227.6%至回顧期間的約43.9百萬港元。有關增加主要由於回顧期間內於不同營銷渠道及多個社交媒體平台進行推廣活動及銀行支出增加，與現金銷售增加一致。

### 財務成本

回顧期間及過往期間，財務成本分別約為1.2百萬港元及約1.0百萬港元。

## **FINANCIAL REVIEW** (Continued)

### **Income tax (expense)/credit**

Income tax credit amounted to approximately HK\$1.5 million for the Previous Period and income tax expense of approximately HK\$6.6 million for the Period Under Review. The tax expense was primarily attributable to profit for the Period Under Review.

### **Profit for the period**

Profit attributable to owners of the Company was approximately HK\$53.9 million for the Period Under Review.

## **INTERIM DIVIDEND**

The Board does not recommend the payment of an interim dividend for the Period Under Review (Previous Period: Nil).

## **財務回顧** (續)

### **所得稅(開支)／抵免**

所得稅抵免於過往期間約為1.5百萬港元，所得稅開支於回顧期間約為6.6百萬港元。稅項開支主要由於回顧期間溢利所致。

### **期內溢利**

回顧期間，本公司擁有人應佔溢利約為53.9百萬港元。

### **中期股息**

董事會不建議就回顧期間派付中期股息(過往期間：零)。

## OTHER INFORMATION 其他資料

### CAPITAL STRUCTURE, LIQUIDITY AND FINANCIAL RESOURCES

The total equity of the Group as at 30 September 2021 was approximately HK\$199.6 million. We continue to maintain a strong financial position with cash and cash equivalents of approximately HK\$112.3 million as at 30 September 2021. Our working capital represented by net current assets was approximately HK\$95.4 million. Based on our steady cash inflows from operations, coupled with sufficient cash and bank balances, we have adequate liquidity and financial resources to meet our working capital requirements and to fund our budgeted expansion plans in this financial year.

As at 30 September 2021, all of our cash and bank balances was denominated in Hong Kong Dollar, United States Dollar and Renminbi.

### LEASE LIABILITIES

As at 30 September 2021, the Group has lease liabilities of approximately HK\$110.3 million.

### CAPITAL COMMITMENTS

As at 30 September 2021, our Group had capital commitments in respect of the acquisition of items of property, plant and equipment of approximately HK\$13.6 million (31 March 2021: Nil).

### INDEBTEDNESS

#### Interest-bearing Bank Borrowings

As at 30 September 2021, our Group had no outstanding interest-bearing bank borrowings (31 March 2021: Nil).

#### Contingent Liabilities and Guarantees

As at 30 September 2021, our Group had no significant contingent liabilities and guarantees (31 March 2021: Nil).

#### Charge of Assets

As at 30 September 2021, there was no charge on the assets of our Group except for the time deposits of approximately HK\$57.4 million (31 March 2021: approximately HK\$57.3 million) pledged for banking facilities as security for credit card instalments programme.

#### Gearing Ratio

As at 30 September 2021, our Group had no interest-bearing borrowings (31 March 2021: Nil).

### 資本架構、流動資金及財務資源

本集團於2021年9月30日的權益總額約為199.6百萬港元。我們持續維持強勁的財務狀況，2021年9月30日的現金及現金等價物約為112.3百萬港元。我們的營運資金（即流動資產淨值）約為95.4百萬港元。根據我們自營運獲得的穩定現金流入，連同足夠的現金及銀行結餘，我們具備足夠的流動資金及財務資源，以應付營運資金需求及於本財政年度撥付預算擴展計劃。

於2021年9月30日，我們的全部現金及銀行結餘以港元、美元及人民幣計值。

### 租賃負債

於2021年9月30日，本集團的租賃負債約為110.3百萬港元。

### 資本承擔

於2021年9月30日，本集團就收購物業、廠房及設備項目的資本承擔約為13.6百萬港元（2021年3月31日：零）。

### 債務

#### 計息銀行借款

於2021年9月30日，本集團並無未償還計息銀行借款（2021年3月31日：零）。

#### 或然負債及擔保

於2021年9月30日，本集團並無重大或然負債及擔保（2021年3月31日：零）。

### 資產抵押

於2021年9月30日，除就銀行融資作為信用卡分期計劃擔保所作抵押的約57.4百萬港元（2021年3月31日：約57.3百萬港元）定期存款外，本集團之資產概無抵押。

### 資產負債比率

於2021年9月30日，本集團並無計息借款（2021年3月31日：零）。



## INDEBTEDNESS (Continued)

### Foreign Currency Risk

Our Group carries out its business in Hong Kong and most of its transactions are denominated in Hong Kong Dollar. Our Group did not experience any material impact or difficulties in liquidity on its operations resulting from the fluctuation in exchange rate, and no hedging transaction or forward contract arrangement was made by the Group during the six months ended 30 September 2021.

### Interest Rate Risk

Our Group has no significant interest rate risk. Our Group currently does not have any specific policies in place to manage interest rate risk and has not entered into any interest rate swap transactions to mitigate interest rate risk, but will closely monitor related risk in the future.

### Significant Investments, Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures, and Future Plans for Material Investments or Capital Assets

Save as disclosed in this report, there were no significant investments held by the Company during the six months ended 30 September 2021, nor were there any material acquisitions and disposals of subsidiaries, associates and joint ventures during the reporting period. Save as disclosed in this report, there is no plan authorised by the Board for other material investments or additions of capital assets as at the date of this report.

## EMPLOYEES AND REMUNERATION POLICIES

As at 30 September 2021, our Group has a total of 322 employees (31 March 2021: 195). Staff costs, including Directors' remuneration, of our Group were approximately HK\$56.4 million for the six months ended 30 September 2021 (six months ended 30 September 2020: approximately HK\$32.7 million). Remuneration is determined with reference to factors such as comparable market salaries and work performance, time commitment and responsibilities of each individual. Employees are provided with relevant in-house and/or external training from time to time. In addition to a basic salary, year-end bonuses are offered to employees who performed outstandingly to attract and retain eligible employees to contribute to our Group.

## EVENT AFTER THE REPORTING PERIOD

On 6 October 2021, Vitae Wellness Beauty Limited, an indirect wholly-owned subsidiary of the Company, as lessee, and Golden Relay Company Limited, an independent third party, as lessor, entered into the lease agreement 2021 in respect of the lease of the entire 22th Floor of Soundwill Plaza, which shall commence from 18 October 2021 and expire on 17 October 2027 (both days inclusive). The Company plans to use this premises as medical aesthetic centre and for the sale of skin care products.

## 債務(續)

### 外匯風險

本集團在香港經營業務，大部分交易均以港元計值。於截至2021年9月30日止六個月，本集團並無因匯率波動而在經營活動的流動資金方面受到任何重大影響或出現困難，且本集團並無作出對沖交易或遠期合約安排。

### 利率風險

本集團並無重大利率風險。本集團目前並未制定任何管理利率風險的具體政策，亦未訂立任何利率互換交易以減低利率風險，惟將會密切監控未來的相關風險。

### 重大投資、重大收購及出售附屬公司、聯營公司及合營企業以及重大投資或資本資產的未來計劃

除本報告所披露者外，本公司截至2021年9月30日止六個月概無持有重大投資，亦無於報告期間重大收購及出售任何附屬公司、聯營公司及合營企業。除本報告所披露者外，於本報告日期，董事會並無就其他重大投資或增加資本資產授權任何計劃。

## 僱員及薪酬政策

於2021年9月30日，本集團合共僱用322名僱員(2021年3月31日：195名)。本集團於截至2021年9月30日止六個月的員工成本(包括董事薪酬)約為56.4百萬港元(截至2020年9月30日止六個月：約32.7百萬港元)。薪酬乃參考多項因素而釐定，如可比較市場薪金以及個人的工作表現、時間投入以及職責。僱員不時獲提供相關內部及/或外部培訓。除基本薪金外，表現出色的僱員可獲年終花紅，以吸引及挽留合資格僱員為本集團作出貢獻。

## 報告期後事項

於2021年10月6日，本公司間接全資附屬公司 Vitae Wellness Beauty Limited(作為承租人)與獨立第三方崇贊有限公司(作為出租人)就租賃金朝陽中心22樓全層訂立2021年租賃協議，租賃期由2021年10月18日至2027年10月17日(包括首尾兩日)屆滿。本公司計劃將該物業用作醫學美容中心及銷售護膚產品。



## PROSPECTS

With the COVID-19 pandemic contained and government measures to revive consumption, the local economy has started on the path of recovery. Seeing the rapid rebound during the Period Under Review, the Group expects the strong and resilient demand for medical aesthetic services to brace expansion of its business and striving for expansion will continue to be the Group's main strategy in the near future for capturing the immense growth potential of the industry.

As one of the Group's core brands which resonate with those looking for top-notch non-surgical aesthetic services, CosMax has doubled its efforts on optimizing the layout of its treatment centre network. The Group has expanded the centre in Soundwill Plaza, 38 Russell Street, Causeway Bay. Moreover, the flagship centre in Central will be relocated to the 10th floor of New World Tower II, 16-18 Queen's Road Central, and is expected to start operation in the first quarter of 2022. The expansion and relocation will increase the total service floor area of CosMax by more than 40% to over 23,000 sq. ft., as such, the Group will be able to access a wider range of customers and fortify its local market penetration.

Drawing on the expertise and extensive industry experience of its management and operation teams, the Group will strive to diversify the business blueprint of VITAE, with the aim of enabling more customers to immerse in breadth and depth of the concept of "Inner health realizes external beauty" through the exceptional customer experience. Further to the two new treatment centres at prime locations that opened in October, one more treatment centre of approximately 7,100 sq. ft. will be opened in Causeway Bay in the first quarter of 2022. The above three centres are expected to provide approximately 60 more treatment rooms in all. The Group has rolled out the FaceGym concept that encourages customers to explore energy awakening the muscles to create a full heart-shaped outline together. Along with that, it has also appointed Fala CHEN as brand spokesperson, who has an excellent industry reputation and commercial value, whom the Group believes will help enlighten its services with a tinge of strength and as a guidepost of aesthetics. The Group also promotes the vision of "balance beauty and health" in collaboration with media platforms, so as to reinforce its customer base and market share.

## 前景

隨著新冠肺炎疫情得到遏制及政府採取措施重振消費，本地經濟開始復甦。鑑於回顧期間的快速反彈，本集團預期醫學美容服務強勁且堅韌的需求將支撐其業務擴張，而致力擴張將繼續為本集團於不久將來把握行業巨大增長潛力的主要策略。

作為本集團核心品牌之一，CosMax為尋求頂尖非手術性美容服務的人士提供服務，並於優化療程中心網絡佈局方面加倍努力。本集團已擴張位於銅鑼灣羅素街38號金朝陽中心的中心。此外，中環旗艦中心將搬遷至皇后大道中16-18號新世界大廈二座10樓，預計於2022年第一季開始營運。有關擴張及搬遷將使CosMax服務的總樓面面積增加逾40%至超過23,000平方呎，因此，本集團將可接觸到更廣泛的客戶，並提高其本地市場滲透率。

本集團憑藉其管理及營運團隊的專業知識及豐富行業經驗，將致力豐富VITAE的業務藍圖，旨在透過卓越的客戶體驗讓更多客戶深入明白「內在的健康，成就外在的美麗」的理念。除了於10月在黃金地段開設的兩個新療程中心外，本集團亦將於2022年第一季在銅鑼灣開設另一個面積約7,100平方呎的療程中心。預期上述三個中心合共將提供約60間額外診療室。本集團已推出FaceGym概念，鼓勵客戶探索喚醒肌肉的承托力，撐起飽滿心形輪廓。同時，其亦邀請陳法拉擔任品牌代言人，彼擁有卓越的行業聲譽及商業價值，本集團相信彼將有助引入動力並作為美學的指標，推動其服務。本集團亦與多個媒體平台合作推廣「平衡美麗與健康」的願景，以鞏固其客戶基礎及市場份額。

## PROSPECTS (Continued)

On top of operating medical aesthetic treatment centres, the Group has continuously introduced sophisticated products of the highest quality to customer. It understands to establish good brand reputation takes time and that building awareness and a good reputation for XOVÉ is a vital and necessary move. As such, it strategically allocates more resources to facilitate both online and offline channel expansion. In addition to the first retail store opened during the Period Under Review, the Group has joined hands with several first-tier shopping malls to launch pop-up stores, with the first in Festival Walk unveiled in October, and three more respectively in Hysan Place, Harbour City and Langham Place are expected to greet customers in the fourth quarter of 2021. Summing up its experience collaborating with Mandarin Oriental Hong Kong, the Group will identify more similar partnership with premium experience providers in the service industry, to help foster brand awareness and customer loyalty. What's more, encouraged by the positive feedback, the Group is sparing no effort to strengthen the online sales platform that serves PRC customers, as well as to collaborate with KOLs on different new media channels, allowing it to seize chances from the consumption upgrades gaining steam in Mainland China.

Empowered by its prominent market position, Miricor has ridden out various economic cycles and challenges. Moreover, the Group has been advancing at its shrewd business acumen and efforts to seek opportunities with promising potential. Looking ahead, it will keep striving to provide premium treatment experiences and high-quality services by going all out to enhance its technologies and devices. As always, through availing to customers its innovative medical aesthetic solutions, the Group is committed to realizing the mission of helping customers “master one’s own beauty and be a masterpiece”, and in turn creates long-term returns for its shareholders.

## 前景(續)

除營運醫學美容療程中心外，本集團亦不斷向客戶推出頂尖品質的尖端產品。本集團深知建立良好的品牌聲譽需時，而為XOVÉ建立知名度及良好聲譽乃至關重要且必要的舉措。因此，其於策略方面分配更多資源以促進線上及線下渠道的擴張。除於回顧期間開設首間零售店外，本集團亦與多個一線商場合作推出快閃店，其中首間快閃店於10月在又一城推出，預期另外三間將於2021年第四季分別在希慎廣場、海港城及朗豪坊與客戶見面。結合與香港文華東方酒店的合作經驗，本集團將物色更多與服務行業的優質體驗供應商的類似合作夥伴關係，以促進品牌知名度及客戶忠誠度。此外，由於獲得正面反饋，本集團正在致力加強服務中國客戶的網上銷售平台，並於不同的新媒體渠道與網紅合作，使其能夠於中國內地消費升級勢頭中把握機遇。

憑藉其卓越市場地位，卓珈已渡過各種經濟周期及挑戰。此外，本集團一直以其靈敏的商業觸覺及努力尋求具良好潛力的機遇，不斷進步。展望未來，本集團將竭力提升其技術及設備，致力提供優質的療程體驗及優質的服務。本集團一如既往，透過為客戶提供創新的醫學美容解決方案，致力於實現協助客戶「成就美麗，成為傑作」的使命，從而為其股東創造長期回報。

## DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND/OR SHORT POSITIONS IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY ASSOCIATED CORPORATION

As at 30 September 2021, interests or short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) which were required (i) pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO), to be notified to the Company and the Stock Exchange; or (ii) pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (iii) pursuant to Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix 10 of the Listing Rules to be notified to the Company and the Stock Exchange, were as follow:

### a. Long positions in shares of the Company:

## 董事及主要行政人員於本公司或任何相聯法團之股份、相關股份及債權證之權益及／或淡倉

於2021年9月30日，本公司董事及主要行政人員於本公司或其任何相聯法團（定義見證券及期貨條例（「證券及期貨條例」）第XV部）的股份、相關股份及債權證中，擁有須(i)根據證券及期貨條例第XV部第7及8分部知會本公司及聯交所的權益或淡倉（包括根據證券及期貨條例有關條文彼等當作或視作擁有的權益及淡倉）；或(ii)根據證券及期貨條例第352條登記於該條所指登記冊的權益或淡倉；或(iii)根據上市規則附錄10所載的上市發行人董事進行證券交易的標準守則知會本公司及聯交所的權益或淡倉如下：

### a. 於本公司股份的好倉：

Name of Director	Capacity/nature of interest	Number of shares held	Percentage of the Company's issued share capital 本公司已發行股本的百分比
董事姓名	身份／權益性質	所持股份數目	股本的百分比
Ms. Lai Ka Yee Gigi ("Mrs. Gigi Ma") 黎珈而女士（「馬黎珈而女士」）	Interest of a controlled corporation (Note 1) 受控制法團權益（附註1）	275,000,000	68.75%

Note:

- Such 275,000,000 Shares are registered in the name of Sunny Bright Group Holdings Limited ("Sunny Bright"), a company beneficially owned as to 50% by Mrs. Gigi Ma and 50% by Mr. Ma Ting Keung, Patrick ("Mr. Patrick Ma"). Mr. Patrick Ma is the spouse of Mrs. Gigi Ma. Therefore, Mrs. Gigi Ma is deemed to be interested in all the Shares held by Sunny Bright under the SFO.

附註：

- 該275,000,000股股份以光彩控股有限公司（「光彩」，一間由馬黎珈而女士及馬廷強先生（「馬廷強先生」）分別實益擁有50%及50%權益的公司）名義登記。馬廷強先生為馬黎珈而女士的配偶。因此，根據證券及期貨條例，馬黎珈而女士被視為於光彩持有的全部股份中擁有權益。

**DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND/OR SHORT POSITIONS IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY ASSOCIATED CORPORATION** (Continued)

董事及主要行政人員於本公司或任何相聯法團之股份、相關股份及債權證之權益及／或淡倉(續)

b. Long positions in shares of an associated corporation:

b. 於相聯法團股份的好倉：

Name of Director	Name of associated corporation	Capacity/nature of interest	Number of shares held	Percentage of the Company's issued share capital 本公司已發行股本的百分比
董事姓名	相聯法團名稱	身份／權益性質	所持股份數目	
Mrs. Gigi Ma	Sunny Bright	Beneficial owner and interest of spouse	2	100%
馬黎珈而女士	光彩	實益擁有人及配偶權益		

Mrs. Gigi Ma is the legal and beneficial owner of 1 issued ordinary share of Sunny Bright, representing 50% of the issued share capital of Sunny Bright. Mr. Patrick Ma is the legal and beneficial owner of the other 1 issued ordinary share of Sunny Bright, representing the remaining 50% of the issued share capital of Sunny Bright. As Mr. Patrick Ma is the spouse of Mrs. Gigi Ma, Mrs. Gigi Ma is deemed to be interested in all the interest registered in Mr. Patrick Ma's name in Sunny Bright. Accordingly, together with the 50% shareholding interest in Sunny Bright registered in Mrs. Gigi Ma's name, Mrs. Gigi Ma is taken to be interested in 100% of the issued share capital of Sunny Bright.

馬黎珈而女士為光彩1股已發行普通股的合法及實益擁有人，佔光彩的50%已發行股本。馬廷強先生為光彩另1股已發行普通股的合法及實益擁有人，佔光彩餘下的50%已發行股本。由於馬廷強先生為馬黎珈而女士的配偶，馬黎珈而女士被視為於光彩以馬廷強先生名義登記的所有權益中擁有權益。因此，連同光彩以馬黎珈而女士名義登記的50%股權，馬黎珈而女士被視為於光彩的100%已發行股本中擁有權益。

Save as disclosed above, as at 30 September 2021, none of the Directors nor chief executive of the Company had registered an interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required (i) pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which were taken or deemed to have under such provisions of the SFO), to be notified to the Company and the Stock Exchange; or (ii) pursuant to section 352 of the SFO, to be entered in the register referred to therein; or (iii) pursuant to Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix 10 of the Listing Rules to be notified to the Company and the Stock Exchange.

除上文所披露者外，於2021年9月30日，概無本公司董事或主要行政人員於本公司或其任何相聯法團(定義見證券及期貨條例第XV部)的股份、相關股份或債權證中，已登記須(i)根據證券及期貨條例第XV部第7及8分部知會本公司及聯交所的權益或淡倉(包括根據證券及期貨條例有關條文當作或視作擁有的權益及淡倉)；或(ii)根據證券及期貨條例第352條登記於該條所指登記冊的權益或淡倉；或(iii)根據上市規則附錄10所載的上市發行人董事進行證券交易的標準守則知會本公司及聯交所的權益或淡倉。

## SUBSTANTIAL SHAREHOLDERS' INTERESTS AND/OR SHORT POSITIONS IN THE SHARES AND UNDERLYING SHARES OF THE COMPANY

As at 30 September 2021, the interests and short positions of the person (other than the Directors and chief executive of the Company) or company which were required to be recorded in the register required to be kept under section 336 of the SFO were as follow:

So far as the Directors are aware, as at 30 September 2021, other than the Directors and chief executive of the Company, the following persons/entities have an interest or a short position in the shares or the underlying shares of the Company which were required to be disclosed to the Company under Divisions 2 and 3 of Part XV of the SFO or required to be recorded in the register of the Company required to be kept under section 336 of the SFO:

Long positions in shares of the Company:

## 主要股東於本公司股份及相關股份之權益及／或淡倉

於2021年9月30日，下列人士(本公司董事及主要行政人員除外)或公司擁有須根據證券及期貨條例第336條記錄在須存置之登記冊的權益及淡倉如下：

就董事所悉，於2021年9月30日，除本公司董事及主要行政人員外，下列人士／實體於本公司的股份或相關股份中擁有須根據證券及期貨條例第XV部第2及3分部向本公司披露或須記錄在根據證券及期貨條例第336條須存置之本公司登記冊的權益或淡倉：

於本公司股份的好倉：

Name	Capacity/Nature of interest	Number of shares held/ interested	Percentage of the Company's issued share capital
姓名／名稱	身份／權益性質	所持／擁有權益的股份數目	本公司已發行股本的百分比
Sunny Bright 光彩	Beneficial Owner 實益擁有人	275,000,000	68.75%
Mr. Patrick Ma 馬廷強先生	Interest in a controlled corporation and interest of spouse (Note 1) 受控制法團權益及配偶權益(附註1)	275,000,000	68.75%
Meitu, Inc. 美图公司	Beneficial Owner 實益擁有人	20,000,000	5%

Note:

- Such 275,000,000 Shares are registered in the name of Sunny Bright, a company beneficially owned as to 50% by Mrs. Gigi Ma and 50% by Mr. Patrick Ma. Mrs. Gigi Ma is the spouse of Mr. Patrick Ma. Accordingly, Mr. Patrick Ma is deemed to be interested in all the Shares held by Sunny Bright under the SFO.

附註：

- 該275,000,000股股份以光彩(一間由馬黎珈而女士及馬廷強先生分別實益擁有50%及50%權益的公司)名義登記。馬黎珈而女士為馬廷強先生的配偶。因此，根據證券及期貨條例，馬廷強先生被視為於光彩持有的全部股份中擁有權益。

## SUBSTANTIAL SHAREHOLDERS' INTERESTS AND/OR SHORT POSITIONS IN THE SHARES AND UNDERLYING SHARES OF THE COMPANY

(Continued)

Save as disclosed above, as at 30 September 2021 and so far as known to the Directors, no person, other than the Directors and chief executive of the Company whose interests are set out in the section "Directors' and Chief Executive's Interests and/or Short Positions in the Shares, Underlying Shares and Debentures of the Company or any Associated Corporation" above, had notified the Company of an interest or short position in the shares or underlying shares of the Company that was required to be recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

## SHARE OPTION SCHEME

The Company has a share option scheme (the "Share Option Scheme") which was approved and adopted by the sole shareholder of the Company by way of written resolutions passed on 19 December 2016 for a term of 10 years from the date of adoption of the Share Option Scheme. The principal terms of the Share Option Scheme are set out in note 14 to the consolidated financial statements.

No share option has been granted, exercised, cancelled or lapsed under the Share Option Scheme since its adoption and there was no outstanding share option as at 30 September 2021.

## DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save for the Share Options Scheme, at no time during the six months ended 30 September 2021 were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any Directors or their respective spouses or children under 18 years of age, or were any such rights exercised by them, or was the Company, its holding company, or any of its subsidiaries and fellow subsidiaries a party to any arrangement to enable the Directors to acquire such rights in any other body corporate.

## PURCHASE, SALE OR REDEMPTION OF SECURITIES

Neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities during the six months ended 30 September 2021.

## 主要股東於本公司股份及相關股份之權益及／或淡倉(續)

除上文所披露者外，於2021年9月30日及就董事所知，並無人士(其權益載列於上文「董事及主要行政人員於本公司或任何相聯法團之股份、相關股份及債權證之權益及／或淡倉」一節的本公司董事及主要行政人員除外)知會本公司彼等於本公司股份或相關股份中擁有須記錄在根據證券及期貨條例第336條本公司須存置之登記冊的權益或淡倉。

## 購股權計劃

本公司有一項購股權計劃(「購股權計劃」)，本公司的唯一股東於2016年12月19日以書面決議案的方式批准及採納該計劃，自採納購股權計劃日期起計為期十年。購股權計劃的主要條款載於綜合財務報表附註14。

自採納起，並無購股權計劃項下的購股權獲授出、行使、註銷或失效，且於2021年9月30日並無尚未行使之購股權。

## 董事購買股份或債權證之權利

除購股權計劃外，本公司於截至2021年9月30日止六個月內任何時間概無授予任何董事或彼等各自之配偶或18歲以下的子女可藉購入本公司股份或債權證而獲益之權利，或彼等亦無行使任何該等權利；本公司、其控股公司或其任何附屬公司及同系附屬公司亦無訂立任何安排致使董事可於任何其他法人團體獲得該等權利。

## 購買、出售或贖回證券

截至2021年9月30日止六個月期間，本公司或其任何附屬公司並無購買、出售或贖回本公司任何上市證券。



## COMPLIANCE OF CODE OF CONDUCT FOR DIRECTORS' SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions Directors of Listed Issuers contained in Appendix 10 of the Listing Rules of the Stock Exchange. Having made specific enquiries to all the Directors, all the Directors confirmed that they had complied with the required standard of dealings and the code of conduct regarding securities transactions by Directors adopted by the Company during the six months ended 30 September 2021.

## COMPLIANCE OF NON-COMPETITION UNDERTAKING

As disclosed in the prospectus of the Company dated 30 December 2016, pursuant to the non-competition undertakings set out in the deed of non-competition dated 19 December 2016, each of our controlling shareholders, namely, Sunny Bright Group Holdings Limited, Mrs. Gigi Ma and Mr. Patrick Ma (collectively the "Controlling Shareholders"), have undertaken to the Company (for itself and on behalf of its subsidiaries) that, amongst other things, each of them does not or will not, and will procure each of their respective close associates not to, directly or indirectly, carry on, participate in, be engaged, interested directly or indirectly, either for their own account or in conjunction with or on behalf of or for any other person in any business in competition with or similar to or is likely to be in competition with the business of the Group upon the Listing of the Company. Details of the deed of non-competition are set out in the paragraph headed "Non-Competition Deed" in the section headed "Relationship with Controlling Shareholders" in the prospectus of the Company dated 30 December 2016.

The independent non-executive Directors have reviewed the implementation of the deed of non-competition and are of the view that the Controlling Shareholders have complied with their undertakings given under the deed of non-competition for the six months ended 30 September 2021.

## COMPETING INTERESTS

As at 30 September 2021, so far as the Directors are aware, none of the Directors, the controlling shareholders and substantial shareholders, neither themselves nor their respective associates (as defined under Rule 8.10 of the Listing Rules) had held any position or had interest in any businesses or companies that were or might be directly or indirectly competing with the business of the Group, or gave rise to any concern regarding conflict of interest.

## 遵守董事進行證券交易之行為守則

本公司已採納聯交所上市規則附錄10所載的上市發行人董事進行證券交易的標準守則。經向全體董事作出特定查詢後，全體董事確認彼等於截至2021年9月30日止六個月內已遵守交易的所需標準及本公司所採納關於董事進行證券交易的行為守則。

## 不競爭承諾的遵守情況

誠如本公司日期為2016年12月30日的招股章程所披露，根據日期為2016年12月19日的不競爭契據所載的不競爭承諾，我們的控股股東（即光彩控股有限公司、馬黎珈而女士及馬廷強先生，統稱「控股股東」）已各自向本公司（為其本身及代表其附屬公司）承諾（其中包括）彼等各自不會或將不會，並將促使彼等各自的緊密聯繫人不會於本公司上市後為其本身或聯同或代表或為任何其他人士直接或間接進行、參與、從事與本集團業務構成競爭或相似或可能構成競爭的任何業務，或直接或間接於當中持有任何權益。不競爭契據的詳情載於本公司日期為2016年12月30日的招股章程「與控股股東的關係」一節「不競爭契據」一段。

獨立非執行董事已審閱不競爭契據的落實情況，並認為控股股東已於截至2021年9月30日止六個月內遵守其於不競爭契據下給予的承諾。

## 競爭利益

於2021年9月30日，就董事所悉，概無董事、控股股東及主要股東自身或彼等各自的聯繫人（定義見上市規則第8.10條）在與本集團業務構成或可能構成直接或間接競爭的任何業務或公司中擔任任何職位或擁有權益，或引起任何與利益衝突有關的顧慮。

## CORPORATE GOVERNANCE CODE

The Company recognises the importance of achieving the highest standard of corporate governance consistent with the needs and requirements of its businesses and the best interest of all of its stakeholders, and the Board is fully committed to doing so. The Board believes that high standards of corporate governance provide a framework and solid foundation for the Group to manage business risks, enhance transparency, achieve high standard of accountability and protect stakeholders' interests.

The Company has adopted the principles and the code provisions set out in the Corporate Governance Code (the "CG Code") contained in Appendix 14 of Listing Rules. During the six months ended 30 September 2021, the Company had complied with all the applicable code provisions of the CG Code, except the deviation stipulated below.

According to the code provision A.2.1 of the CG Code, the roles of the chairman and chief executive should be separate and should not be performed by the same individual. Under the current management structure of the Company, Ms. LAI Ka Yee Gigi (Mrs. Gigi Ma) is the chairlady of the Board (the "Chairlady") and chief executive officer of the Company (the "Chief Executive Officer"). As Mrs. Gigi Ma has been leading the Group as the Group's Chief Executive Officer and sole director of each of major subsidiaries since the establishment of the relevant major subsidiaries, the Board believes that it is in the best interest of the Group to continue to have Mrs. Gigi Ma acting as the Chairlady and Chief Executive Officer for more effective management and planning of the Group. Therefore, the Board considers that the deviation from provision A.2.1 of the CG Code is appropriate in the circumstances and currently does not propose to separate the functions of chairman and the chief executive officer.

## 企業管治守則

本公司深明達致配合其業務的需要及要求且符合其所有持份者最佳利益之最高標準企業管治之重要性，而董事會一直致力進行有關工作。董事會相信，高標準企業管治能為本集團奠定良好架構，紮穩根基，不單有助管理業務風險及提高透明度，亦能維持高標準問責性及保障持份者之利益。

本公司已採納上市規則附錄14所載的企業管治守則（「企業管治守則」）的原則及守則條文。截至2021年9月30日止六個月內，本公司已遵守企業管治守則的所有適用守則條文，惟下述偏離情況除外。

根據企業管治守則的守則條文第A.2.1條，主席及行政總裁的職權應予以區分，不應由同一人擔任。根據目前本公司的管理架構，黎珈而女士（馬黎珈而女士）為本公司的董事會主席（「主席」）及行政總裁（「行政總裁」）。由於馬黎珈而女士一直擔任本集團行政總裁領導本集團，並在相關主要附屬公司成立以來一直擔任各主要附屬公司之唯一董事，董事會相信，馬黎珈而女士繼續擔任主席及行政總裁符合本集團最佳利益，以更有效管理及規劃本集團。因此，董事會認為，偏離企業管治守則條文第A.2.1條的情況屬適當，目前並不建議區分主席與行政總裁的職責。



## AUDIT COMMITTEE

The Company has established an audit committee with written terms of reference following the Rules 3.21 to 3.24 of the Listing Rules. The audit committee consists of three independent non-executive Directors, namely Mr. Cheng Yuk Wo, who has the appropriate auditing and financial related management expertise and serves as the chairman of the audit committee, Mr. Cheng Fu Kwok David and Mr. Li Wai Kwan. The audit committee has reviewed the unaudited condensed consolidated financial statements of the Group for the six months ended 30 September 2021 and this report.

By order of the Board

**Miricor Enterprises Holdings Limited**

**Lai Ka Yee Gigi**

*Chairlady & Chief Executive Officer*

Hong Kong, 15 November 2021

## 審核委員會

本公司已成立審核委員會，其書面職權範圍已遵守上市規則第3.21至3.24條。審核委員會由三名獨立非執行董事組成，由具備合適核數及財政相關管理專業的鄭毓和先生出任審核委員會主席，其餘成員為鄭輔國先生及李偉君先生。審核委員會已審閱本集團截至2021年9月30日止六個月的未經審核簡明綜合財務報表及本報告。

承董事會命

卓珈控股集團有限公司

主席兼行政總裁

黎珈而

香港，2021年11月15日

